BPTH (Bio-Path Holdings) 10-Year RORE % : -20.06% (As of Mar. 2026)


What is Bio-Path Holdings 10-Year RORE %?

Bio-Path Holdings BPTH -2.13% 10-Year RORE % is -20.06 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 613 Biotechnology companies, Bio-Path Holdings ranks worse than 73.08% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Bio-Path Holdings's 10-Year RORE % for the quarter that ended in Mar. 2026 was -20.06%.

The industry rank for Bio-Path Holdings's 10-Year RORE % or its related term are showing as below:

BPTH's 10-Year RORE % is ranked worse than
73.08% of 613 companies
in the Biotechnology industry
Industry Median: -6.37 vs BPTH: -20.06

Bio-Path Holdings  (OTCPK:BPTH) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Bio-Path Holdings 10-Year RORE % Related Terms


Bio-Path Holdings 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings 10-Year RORE % Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.23 -4.78 -9.14 -10.31 -19.32

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.32 -20.80 -24.58 -26.25 -20.06

BPTH vs VBIO, HEPA, AXIM: 10-Year RORE % Comparison

For the Biotechnology subindustry, Bio-Path Holdings's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings 10-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's 10-Year RORE % falls into.



Bio-Path Holdings 10-Year RORE % Calculation

Bio-Path Holdings's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.69--228 )/( -1133.367-0 )
=227.31/-1133.367
=-20.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of -20.06 mean?
Bio-Path Holdings (BPTH) has a 10-Year RORE % of -20.06 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #448 out of 613 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Bio-Path Holdings' 10-Year RORE % too high?
Bio-Path Holdings' current 10-Year RORE % is -20.06. Based on the distribution chart, Bio-Path Holdings ranks #448 out of 613 companies in the Biotechnology industry, which is below the industry midpoint.
How does Bio-Path Holdings' 10-Year RORE % compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #448 out of 613 companies for 10-Year RORE %. This places Bio-Path Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current 10-Year RORE % is -20.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current 10-Year RORE % of -20.06. The current 10-Year RORE % is -20.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current 10-Year RORE % is -20.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.